BR112013010844A2 - nova endolisina - Google Patents

nova endolisina

Info

Publication number
BR112013010844A2
BR112013010844A2 BR112013010844A BR112013010844A BR112013010844A2 BR 112013010844 A2 BR112013010844 A2 BR 112013010844A2 BR 112013010844 A BR112013010844 A BR 112013010844A BR 112013010844 A BR112013010844 A BR 112013010844A BR 112013010844 A2 BR112013010844 A2 BR 112013010844A2
Authority
BR
Brazil
Prior art keywords
polypeptide
relates
present
fusion protein
fragment
Prior art date
Application number
BR112013010844A
Other languages
English (en)
Inventor
Cecilia Valente Rodriguez Azeredo Joana
Dorothea Kluskens Leonardus
Walmagh Maarten
Lavigne Rob
Roberto Branco Dos Santos Silvio
Original Assignee
Katholieke Univ Leuven K U Leuven R&D
Univ Of Minho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven R&D, Univ Of Minho filed Critical Katholieke Univ Leuven K U Leuven R&D
Publication of BR112013010844A2 publication Critical patent/BR112013010844A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3571—Microorganisms; Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01028—N-Acetylmuramoyl-L-alanine amidase (3.5.1.28)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Virology (AREA)
  • Dentistry (AREA)

Abstract

nova endolisina. a presente invenção se refere a um polipeptídeo com atividade de endolisina compreendendo uma sequência de amino ácido de acordo com seq id no. 1 e fragmentos ou derivados da mesma, ou proteínas de fusão derivadas da mesma. adicionalmente, a presente invenção se refere a moléculas de ácido nucleico que codificam o referido polipeptídeo ou proteína de fusão, vetores compreendendo as referidas moléculas de ácido nucleico e células hospedeiras compreendendo ou as referidas moléculas de ácido nucleico ou os referidos vetores. adicionalmente, a presente invenção se refere ao referido polipeptídeo, fragmento, derivado ou proteína de fusão para uso como um medicamento, em particular para o tratamento ou prevenção de infecções bacterianas gram-negativas, como meio diagnóstico, como substância cosmética ou como agente de sanitização. a presente invenção também se refere ao uso do referido polipeptídeo, fragmento, derivado ou proteína de fusão para o tratamento ou prevenção de contaminação bacteriana gram-negativa de produto alimentício, de equipamento de processamento de alimentos, de instalações de processamento de alimentos, de superfícies entrando em contato com produto alimentício, de dispositivos médicos, de superfícies em hospitais e cirurgias. adicionalmente, a presente invenção se refere a uma composição farmacêutica compreendendo o referido polipeptídeo, fragmento, derivado ou proteína de fusão.
BR112013010844A 2010-11-03 2011-11-03 nova endolisina BR112013010844A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1018518.9A GB201018518D0 (en) 2010-11-03 2010-11-03 Novel endolysin
PCT/EP2011/069336 WO2012059545A1 (en) 2010-11-03 2011-11-03 Novel endolysin

Publications (1)

Publication Number Publication Date
BR112013010844A2 true BR112013010844A2 (pt) 2019-09-24

Family

ID=43401687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013010844A BR112013010844A2 (pt) 2010-11-03 2011-11-03 nova endolisina

Country Status (8)

Country Link
US (1) US20140017224A1 (pt)
EP (1) EP2635676B1 (pt)
JP (1) JP2014500714A (pt)
CN (1) CN103201381A (pt)
BR (1) BR112013010844A2 (pt)
GB (1) GB201018518D0 (pt)
TW (1) TW201300539A (pt)
WO (1) WO2012059545A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024421A1 (en) * 2011-08-12 2013-02-21 Universidade Do Minho Peptides and derivatives thereof for detection and control of salmonella
RU2547584C2 (ru) * 2012-12-05 2015-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Гидролаза пептидогликана, экспрессионная плазмида, содержащая фрагмент днк, кодирующий гидролазу пептидогликана, бактерия-продуцент и способ микробиологического синтеза гидролазы пептидогликана
WO2015070911A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
US10329550B2 (en) 2014-02-14 2019-06-25 Lysando Ag Antimicrobial agents
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN105062992B (zh) * 2015-07-20 2018-05-11 昆明理工大学 一种细胞内溶素和编码此细胞内溶素的多核苷酸
WO2017203471A1 (en) * 2016-05-27 2017-11-30 Sasinapas Co., Ltd. Endolysin variant
WO2018109229A1 (en) * 2016-12-16 2018-06-21 Universidade Do Minho Novel endolysin
AU2018384790A1 (en) * 2017-12-12 2020-07-30 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
AU2019276253A1 (en) 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial proteins
KR20220007123A (ko) * 2019-05-08 2022-01-18 파고메드 바이오파르마 게엠베하 신규 가드네렐라 엔도리신 및 이의 용도
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria
CN114807104B (zh) * 2022-04-11 2024-02-20 西南大学 肺炎克雷伯菌噬菌体裂解酶及其制备方法和应用
CN116536289B (zh) * 2023-06-21 2023-09-15 中国农业科学院生物技术研究所 具有溶菌活性的几丁质酶及其突变体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents

Also Published As

Publication number Publication date
CN103201381A (zh) 2013-07-10
EP2635676B1 (en) 2015-04-22
EP2635676A1 (en) 2013-09-11
GB201018518D0 (en) 2010-12-15
JP2014500714A (ja) 2014-01-16
TW201300539A (zh) 2013-01-01
WO2012059545A1 (en) 2012-05-10
US20140017224A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
BR112013010844A2 (pt) nova endolisina
EA201270322A1 (ru) НОВЫЙ ЭНДОЛИЗИН OBPgpLYS
BRPI1015192A2 (pt) agentes antimicrobianos
MX2011013453A (es) Agentes antimicrobianos.
Mercer et al. Antimicrobial susceptibility testing of antimicrobial peptides to better predict efficacy
Mine et al. Antimicrobial peptides released by enzymatic hydrolysis of hen egg white lysozyme
BR112012026880A2 (pt) método de redução de biofilmes
EA201370145A1 (ru) Антимикробные средства
Pane et al. Identification of novel cryptic multifunctional antimicrobial peptides from the human stomach enabled by a computational–experimental platform
Menousek et al. Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300
WO2010023207A3 (en) Antimicrobial agents
Wang et al. Morin hydrate attenuates Staphylococcus aureus virulence by inhibiting the self‐assembly of α‐hemolysin
EA201991233A1 (ru) Новый эндолизин
BR112012027315A2 (pt) polipeptídeo quimérico, composição, molécula de ácido nucleico quimérica, vetor, célula hospedeira, processo de produção de um polipeptídeo, vacina combinada, e, métodos para a indução de uma resposta imunológica e para prevenir ou tratar uma infecção ou doença
JP2014500714A5 (pt)
BR112012027055A2 (pt) agente estabilizante para proteínas farmacêuticas.
CN111971058A (zh) 对铜绿假单胞菌具有细菌活性的溶素及其衍生物的鉴定
EP3313862B9 (en) Broad-spectrum anti-infective peptides
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
Zhou et al. Antimicrobial activity of the antibacterial peptide PMAP-36 and its analogues
CN112368010A (zh) 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性细菌的用途
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
Xu et al. Cortex cercis chinensis granules attenuate Streptococcus pneumoniae virulence by targeting pneumolysin
BR112017020008A2 (pt) peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele
TH142222A (th) เอ็นโดไลซิน OBPgpLYS ใหม่ (NEW ENDOLYSIN OBPGLYS)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.